Ascletis Pharma Inc. (HKEX: 1672) announced on August 30 that the first participant has been dosed in its global Phase III program for ASC30, an investigational once-daily oral small molecule GLP-1 receptor agonist for chronic weight management. The program consists of two pivotal trials, AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450), expected to enroll roughly 4,600 participants across the U.S., Europe, and Canada. Ascletis says it expects topline data in the third quarter of 2028, an FDA New Drug Application submission by the end of 2028, and a European Medicines Agency filing in early 2029, putting any potential approval and launch several years out even if the trials succeed.

Trial Design

The two trials split by patient population: AURORA-1 enrolls adults with obesity or overweight who do not have type 2 diabetes, while AURORA-2 enrolls those who do. Both are randomized, double-blind, placebo-controlled studies testing three maintenance doses of ASC30, 20 mg, 40 mg, and 60 mg, against placebo over 72 weeks, with the primary endpoint being percentage change in body weight from baseline at week 72. That is a substantially longer and larger commitment than the Phase II work that preceded it.

What the Phase II Data Actually Showed

Ascletis CEO Jinzi Jason Wu described ASC30 as entering this stage backed by a competitive Phase II weight loss profile, favorable gastrointestinal tolerability, and no observed hepatic safety signals, but this release does not restate the actual numbers behind that claim. According to Ascletis’ own December 2025 Phase II results, independently reported by Fierce Biotech, a 13-week U.S. study of 125 participants found placebo-adjusted weight loss of 5.4%, 7%, and 7.7% at the 20 mg, 40 mg, and 60 mg doses respectively, all described as statistically significant, with no plateau observed by week 13. The company also reported that when titrated weekly to target dose, ASC30’s vomiting rate was roughly half the published rate for orforglipron, Eli Lilly’s competing oral GLP-1 candidate, and that no elevations in liver enzymes or bilirubin were observed.

How That Compares to Rivals

Those results should be read in context rather than as a settled verdict on where ASC30 ranks among obesity drugs. Cross-trial comparisons in this category are inherently limited by differences in trial length, dosing schedule, and patient population, and Fierce Biotech’s own coverage of the December data noted that Pfizer’s injectable oral GLP-1 candidate posted higher placebo-adjusted weight loss, up to 11.3% to 12.3% in separate Phase II readouts, though over different timeframes and dosing routes that make a direct comparison imprecise. In short, ASC30’s Phase II data are real, positive, and statistically significant, but they do not yet establish it as unambiguously best-in-class against a crowded field of oral and injectable rivals; that will depend on how the drug performs over the longer 72-week Phase III duration.

A Separate Injectable Formulation

Ascletis also has separate injectable formulations of ASC30 in development. A 24-week Phase II study of a once-monthly subcutaneous depot formulation, reported in March 2026, found placebo-adjusted weight loss peaking at 7.5% at week 16 after three monthly doses, before declining to 5.8% by week 24, with weight loss maintained for roughly four months after the final injection, suggesting a possible quarterly-dosing maintenance option distinct from the daily oral tablet now in Phase III. That injectable program is separate from the AURORA trials and is not addressed further in this release.

The Broader Pipeline

Beyond the core ASC30 programs, Ascletis says it is developing several fixed-dose combinations built around the same molecule, pairing ASC30 with its own GIP agonist and amylin agonist candidates to create dual and triple-agonist pills, following a broader industry trend toward combining multiple metabolic hormone targets in a single treatment rather than relying on GLP-1 alone. None of those combination programs are part of the AURORA Phase III trials specifically, and none have Phase III data of their own yet.

Financial Position

On the financial side, Ascletis says it has sufficient cash on hand to fund operations into 2029, which it describes as enough to cover the AURORA program through its planned U.S. and European regulatory submissions without needing additional financing before then; that is the company’s own characterization of its balance sheet rather than independently audited runway guidance. The release also states that ASC30 has the potential to become the second oral small molecule GLP-1 receptor agonist available in the U.S. and Europe if approved, an explicitly conditional claim that depends both on ASC30 clearing Phase III and on which competing oral candidates reach approval first.

What’s Next

For investors, the practical takeaway is that this is a real, well-defined clinical milestone, first dosing in a large, well-structured Phase III program, but it is also the start of a multi-year process with no efficacy or safety readout expected before the third quarter of 2028. This article covers a clinical trial milestone and previously reported Phase II data and is not investment or medical advice; patients should consult a qualified healthcare professional regarding weight management treatment options.

Sources

Ascletis Pharma Inc.: Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management, PRNewswire, August 30, 2026.

Fierce Biotech: China’s Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study, cited for independently reported Phase II data and competitive context.

Fierce Biotech: Ascletis posts phase 2 obesity data, touts potential quarterly GLP-1 dosing, cited for injectable formulation Phase II data.

Editorial Disclosure

This article is based on a press release issued by Ascletis Pharma Inc. on August 30, 2026, distributed via PRNewswire, with Phase II clinical data drawn from independently reported trade press coverage cited above rather than restated from this release alone. Ascletis Pharma trades on the Hong Kong Stock Exchange under the ticker 1672. BioTech Stocks Daily was not compensated for this coverage. Statements regarding ASC30’s competitive positioning, regulatory timeline, and cash runway are forward-looking or company-sourced characterizations; no Phase III efficacy or safety data exists yet. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.